drugset / Trial / NCT07389577
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis® in subjects with wAMD.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2023-12-20
- Completion
- 2024-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JL14002 | Monoclonal antibody | 0.5 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |